Regenerative peptide development for skin and deeper connective tissue. Topical cosmetic skin care leads our product-development approach, alongside a parallel investigational oral BPC-157 pathway for deeper tissue repair/regeneration.
CURRENT FOCUS / CANDIDATE & FORMULATION DEVELOPMENT
How this program emerged
A new application. A distinct development path.
Our oncology inquiry led us to regenerative peptide development for skin and deeper connective tissue. That exploration opened a route toward products with nearer-term commercial potential.
Our formulation strategy focuses on identified peptide candidates for topical cosmetic use, assessing stability, compatibility, safety and intended performance before selecting a final product.
In parallel, published BPC-157 studies in animal models motivate an oral-formulation research opportunity for deeper tissue repair/regeneration, including tendon and ligament injuries. This therapeutic program is expected to take longer to develop than cosmetic skin care because oral exposure, dose, safety and efficacy must be established for a defined indication.
Working product profile / Subject to evaluation
Start with one focused skin-care product.
A peptide-containing facial moisturizer for adults concerned with dryness and the visible appearance of aging skin.
This is a development assumption, not a finalized formula, launch commitment or established benefit of a Wright Health product.
Proposed format
A topical facial cream or moisturizer. Peptide selection and concentration remain to be determined.
Intended cosmetic objectives
Moisturization, skin conditioning and appearance-related performance, with any eventual claims tied to product-specific evidence.
Formulation feasibility
Evaluate ingredient compatibility, stability, preservation, packaging compatibility and manufacturability.
Safety and performance
Plan appropriate safety substantiation and tolerability work, followed by studies suited to the intended cosmetic claims.
Meaningful comparison
Where practical, compare candidate formulations with a matched vehicle or a relevant reference product. Separate the base moisturizer's contribution from any incremental peptide effect.
Advance decision
Review formulation performance, safety evidence, differentiation and potential production economics before committing to a commercial route.
Parallel therapeutic research / Oral BPC-157
Explore deeper tissue repair/regeneration.
Develop an oral BPC-157 candidate for evaluation in tendon and ligament injury models, with sprains, strains and wound repair among the potential research applications.
The formulation and first indication remain to be selected. This is an investigational development objective; clinical safety and benefit for these uses have not been established.
Proposed route
An oral formulation developed in parallel with topical cosmetic skin care, through a separate therapeutic development program.
Delivery feasibility
Evaluate peptide identity and purity, formulation stability, gastrointestinal degradation and systemic exposure before assuming delivery to deeper connective tissue.
Pre-clinical proof of concept
Plan relevant in vitro work followed by appropriate in vivo injury models to assess biological activity, tissue repair, function and safety. Model and endpoint selection will follow the intended indication.
Formulation optimization
Use the results to refine stability and exposure and evaluate potential therapeutic benefit. Compare with appropriate controls and assess reproducibility.
Longer development horizon
Progression requires a defined safety package, manufacturing controls, regulatory assessment and, where authorized, clinical studies. Published animal findings do not establish an effective oral treatment in people.
Published foundations / Independent of Wright Health
Published foundations for skin and deeper tissue research.
These publications explain the research context. Wright Health did not conduct these studies; its own candidates require separate evaluation.
HUMAN STUDY / 12 WEEKS / 93 PARTICIPANTS
A topical peptide formulation evaluated in humans
Robinson and colleagues compared a moisturizer containing palmitoyl pentapeptide with its moisturizer control in a randomized, double-blind, split-face study. They reported improvements in measured fine-line and wrinkle appearance.
What this does and does not establish
The study involved a specific formulation and 93 Caucasian women aged 35-55. Its results cannot establish the performance of a future Wright Health product or other peptides.
Cerovecki and colleagues studied healing after medial collateral ligament transection in rats, including an oral drinking-water regimen. They reported functional, biomechanical and histological improvements with BPC-157.
What this does and does not establish
This was an animal injury study, not a human sprain or strain trial. Oral administration in rats does not establish human oral bioavailability, dosing, safety or clinical benefit, or validate a Wright Health formulation.
Staresinic and colleagues reported improved healing measures after Achilles tendon transection in rats and effects on tendon-cell growth in vitro. This study provides a separate experimental precedent for deeper tissue research.
What this does and does not establish
The tendon study used intraperitoneal administration in rats. It does not validate an oral formulation or establish treatment efficacy for human tendon injuries.
Topical formulations intended for skin conditioning, moisturization and appearance-related benefits, including the appearance of aging skin.
Priority: candidate selection and formulation evaluationTHERAPEUTIC RESEARCH
Skin repair
Potential peptide applications in wounds, burns, lacerations and scarring. These remain research areas requiring indication-specific safety and efficacy studies.
Next: define a focused target product profilePARALLEL THERAPEUTIC RESEARCH
Deeper tissue repair/regeneration
An oral BPC-157 candidate is planned for evaluation in tendon and ligament injuries. Muscle repair and other deeper tissue applications remain research opportunities. Delivery, biological activity, safety and efficacy must be established for each selected use.
Next: assess oral formulation, exposure and injury models
Two development routes
Intended use determines the route.
01 / COSMETIC PRODUCTS
Appearance-focused skin care
Formulation, stability, safety substantiation and appropriate performance testing support a potential cosmetic product. Cosmetic positioning does not establish treatment or regeneration claims.
02 / INVESTIGATIONAL THERAPEUTICS
Skin repair & deeper tissue repair/regeneration
Oral BPC-157 and other therapeutic peptide objectives require a separate regulatory assessment, pre-clinical in vitro and appropriate in vivo evidence and, where applicable, an IND and clinical studies.
Commercial pathways
Develop with partners. Choose the route from the results.
Our intended starting approach is collaboration with an established formulation and manufacturing laboratory. Licensing and a Wright-owned brand remain potential routes.
FIRST / DEVELOPMENT PARTNERSHIP
Establish formulation feasibility
Seek appropriate laboratory capabilities for formulation iterations, stability and safety work, manufacturing requirements and cost estimates. No commercial partner or agreement is implied.
OPTION / LICENSING
Build a transferable development package
Consider licensing if results support a differentiated formulation, useful know-how or other transferable rights. Ownership, freedom to operate and any potential IP protection require separate assessment.
OPTION / WRIGHT-OWNED BRAND
Assess demand and production economics
A proprietary brand may be appropriate if product-specific evidence, customer interest, manufacturing capacity and commercial economics justify the investment.
Development scope
Final topical peptide selection, formulation and product claims will follow evaluation. BPC-157 is an investigational therapeutic candidate here, not a product offered for treatment. Human safety and efficacy for the proposed deeper tissue uses have not been established. Cosmetic products require their own adequate safety substantiation.